Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

 Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026

Vinge advises Consolid Equity on the sale of Road Mobility Services to Nalka

 Vinge has advised Consolid Equity on the sale of Road Mobility Services to Nalka. In connection with the transaction, Consolid, entrepreneurs and management will reinvest and remain as minority shareholders alongside Nalka as the new majority shareholder.
August 28, 2026

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

 Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026